RLMD — Relmada Therapeutics Share News
0.000.00%
Last trade - 00:00- $350.94m
- $133.21m
Brief: Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance
Relmada says independent analysis shows depression treatment unlikely to meet main trial goal
Brief: Relmada Therapeutics Initiates Phase 1 Dosing With REL-P11 For Metabolic Disease
Relmada Therapeutics Inc reports results for the quarter - Earnings Summary
Relmada Therapeutics Inc expected to post a loss of 64 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Aerovironment, Insulet, Viasat
Relmada Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.59
Relmada Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
Relmada Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
Relmada Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: Relmada Therapeutics Q1 EPS USD -0.72
Relmada Therapeutics Inc expected to post a loss of 85 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Dick's Sporting Goods, Nvidia, PVH
Relmada Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Relmada Therapeutics Q4 EPS USD -0.84
Relmada Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx
U.S. STOCKS ON THE MOVE-Lululemon, Copper miners, Gold miners